← FDA DRUG APPROVALS

FDA NDA · NDA010392

ATARAX

Sponsor: PFIZER

APPLICATION
NDA010392
TYPE
NDA
ORIGINAL APPROVAL
1956-04-12
LATEST ACTION
2001-03-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ATARAX · ReferenceDiscontinued
HYDROXYZINE HYDROCHLORIDE 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
ATARAX · ReferenceDiscontinued
HYDROXYZINE HYDROCHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
ATARAX · ReferenceDiscontinued
HYDROXYZINE HYDROCHLORIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
ATARAX · ReferenceDiscontinued
HYDROXYZINE HYDROCHLORIDE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2001-03-21Labeling · Supplement 41 · standardLetterAP
2000-03-27Manufacturing (CMC) · Supplement 40 · standardAP
1998-01-16Manufacturing (CMC) · Supplement 38 · standardAP
1998-01-16Manufacturing (CMC) · Supplement 36 · standardAP
1994-07-12Manufacturing (CMC) · Supplement 37 · standardAP
1985-05-20Labeling · Supplement 31AP
1979-05-21Labeling · Supplement 21AP
1974-12-02Labeling · Supplement 8AP
1956-04-12Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →